Showing results filtered by:
2 Results
Hyperimmune Intravenous Immunoglobulin Does Not Improve Outcomes for Adults Hospitalized with COVID-19
January 27, 2022
A clinical trial has found that the combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, is not more effective than remdesivir alone for treating adults hospitalized with the disease. The trial also found that the safety of this experimental treatment may vary depending on whether a person naturally generates SARS-CoV-2-neutralizing antibodies before receiving it. The results of the multinational Phase 3 trial were published today in the journal The Lancet.
Media Availability—NIH Officials Highlight COVID-19 Vaccine Facts, Unknowns for Healthcare Providers
January 18, 2021
NIAID Director urges healthcare providers to be able to explain the latest data supporting the safety and efficacy of vaccines for COVID-19.